2024 International Symposium of Gastrointestinal Oncology (ISGIO)

Hitting the Target: Molecular Tumor Board With the Experts

Non-CE Symposium Breakfast

Medical Crossfire: Where Should We Incorporate Radioligand Therapy for Advanced NETs? PRRT Upfront

Medical Crossfire: Where Should We Incorporate Radioligand Therapy for Advanced NETs? Other Therapies First

Optimizing Chemotherapy Backbone in Metastatic PDAC Trials

Case Presentation: Novel Treatments for Localized HCC

Shifts in the Use of Multimodality Therapy for Localized HCC

Case Presentation: Systemic Therapy for Advanced HCC

How Do We Select the Best Therapy for Frontline Advanced HCC?

Hot Seat on Debatable Topics in Biliary Tract Cancer

Case Presentation: Contemporary Challenges in Non-Metastatic EG Cancer

2024 Highlights and Principles for Management of Non-Metastatic EG Cancers

Case Presentation: Contemporary Challenges in Metastatic EG Cancer

2024 Highlights and Principles for Management of Metastatic EG Cancers

Multidisciplinary Management of Locally Advanced Rectal Cancer

Where We Stand in 2024 Using ctDNA for Colon Cancer

Case 1: MSI-H Local Colon Cancer, Considerations for Nonoperative Management

Case 2: Immunotherapy for Localized Rectal Cancer

Immunotherapy in MSS CRC: What Has Changed in 2024?

What's Coming in Targeted Therapy for Advanced CRC?

Medical Crossfire Debate: Should 2 Drugs or 1 Drug Be the Standard of Care for MSI-H mCRC? Case Presentation

Medical Crossfire Debate: Should 2 Drugs or 1 Drug Be the Standard of Care for MSI-H mCRC? One Drug

Medical Crossfire Debate: Should 2 Drugs or 1 Drug Be the Standard of Care for MSI-H mCRC? Two Drugs